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Abstract  
 
Objective 
Observational studies show an association between ferritin and type 2 diabetes 
(T2D), suggesting a role of high iron stores for T2D development. However, ferritin is 
influenced by factors other than iron stores, which is less the case for other 
biomarkers of iron metabolism. We investigate associations of ferritin, transferrin 
saturation (TSAT), serum iron and transferrin with T2D incidence, to clarify the role 
of iron in the pathogenesis of T2D.  
 
Research and Design Methods 
The EPIC-InterAct study includes 12,403 incident T2D cases and a representative 
sub-cohort of 16,154 individuals from a European cohort with 3.99 million person-
years of follow-up. We studied the prospective association of ferritin, TSAT, serum 
iron and transferrin with incident T2D in 11,052 cases and a random sub-cohort of 
15,182 individuals and assessed whether these associations differed by subgroups 
of the population.  
 
Results 
Higher levels of ferritin and transferrin were associated with a higher risk of T2D [HR 
in men and women, respectively: 1.07 (95% CI: 1.01; 1.12) and 1.12 (1.05; 1.19) per 
100 μg/L higher ferritin level; 1.11 (1.00; 1.24) and 1.22 (1.12; 1.33) per 0.5 g/L 
higher transferrin level] after adjustment for age, centre, BMI, physical activity, 
smoking status, education, hsCRP, ALT and GGT. Elevated TSAT (≥45% versus 
<45%) was associated with a lower risk of T2D in women [0.68 (0.54; 0.86)] but was 
not statistically significantly associated in men [0.90 (0.75; 1.08)]. Serum iron was 
not associated with T2D. The association of ferritin with T2D was stronger among 
leaner individuals (pinteraction<0.01).  
 
Conclusions 
The pattern of association of TSAT and transferrin with T2D suggests that the 
underlying relationship between iron stores and T2D is more complex than the 
simple link suggested by the association of ferritin with T2D.   
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Hereditary hemochromatosis (HHC), a genetic disorder characterized by systemic 
iron overload, is reported to be associated with diabetes mellitus (1). Similarly, an 
overrepresentation of diabetes mellitus cases has also been described among 
individuals with conditions of acquired iron overload, such as thalassemia major (2). 
This raises the question whether high levels of body iron is a risk factor for type 2 
diabetes in the general population, as this would have implications for the prevention 
and treatment of type 2 diabetes. Cross-sectional and prospective population studies 
report a positive association between ferritin and type 2 diabetes (3,4). However, 
although ferritin is considered a marker of iron stores in healthy individuals (5–7), it is 
also an acute phase reactant and is influenced by inflammation, liver disease and 
insulin resistance, which are also associated with type 2 diabetes (8–11).  
 
The use of other commonly measured biomarkers of iron metabolism may provide 
additional information on the role of iron in the pathogenesis of type 2 diabetes, 
because they reflect different aspects of iron metabolism and are less influenced by 
the above mentioned conditions. Transferrin is the iron binding protein in circulation 
and its levels rise with increasing iron requirements. Serum iron is difficult to interpret 
in isolation as it has a diurnal variation and hence varies significantly without 
changes in total body iron (12). Transferrin saturation (TSAT) is the proportion of 
transferrin bound to serum iron and is in part a marker of iron absorption, as it 
reflects the proportion of circulating iron in the context of iron requirements. TSAT is 
elevated in the presence of non-transferrin bound iron, which in turn is responsible 
for iron-related oxidative damage (13,14).  
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We investigated the association of ferritin, TSAT, serum iron and transferrin with 
incident type 2 diabetes in a large prospective European case-cohort study. We also 
assessed whether these associations have a threshold effect or differ by subgroups 
of the population, such as individuals not presenting signs of conditions commonly 
associated with hyperferritinemia.  
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RESEARCH DESIGN AND METHODS 
 
The EPIC-InterAct study 
 
Participants and study design 
The InterAct study is a large case-cohort study of incident type 2 diabetes nested 
within the European Prospective Investigation into Cancer and Nutrition (EPIC) 
study, the design and population characteristics of which have been published 
previously (15). In brief, a total of 12,403 incident cases of type 2 diabetes were 
ascertained and verified during 3.99 million person-years of follow-up (mean follow-
up of 11.7 years) of 340,234 eligible EPIC participants (men and women aged 20-80 
years at baseline, with a stored blood sample and reported diabetes mellitus status). 
The subcohort (n=16,154), which was a representative sample of the original cohort, 
was identified by randomly selecting individuals from each center. We excluded 
individuals who had prevalent clinically diagnosed diabetes at baseline. By design 
there are individuals with incident diabetes that were also randomly selected into the 
subcohort (n=778) and these are included as cases in case-cohort analyses (15). A 
detailed breakdown of participants with data on the iron biomarkers and covariates 
are detailed in the results. Participants gave written informed consent and the study 
was approved by the local ethics committee in the participating countries and the 
Internal Review Board of the International Agency for Research on Cancer. 
 
 
 
Measurements 
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Standardized information was collected by questionnaire and physical examination 
at recruitment as part of EPIC. Participants were asked about their level of 
education, smoking status and alcohol consumption (which was subsequently 
converted into mean g/day). Diet and physical activity were assessed using 
questionnaires (15,16). Presence of a family history of type 2 diabetes, defined as 
type 2 diabetes in a first degree relative, was asked in most cohorts except those in 
Italy, Spain, Oxford and Heidelberg. Menopausal status was defined as menopausal 
(post-menopausal or post-ovariectomy) and non-menopausal (pre- or peri-
menopausal). A blood sample was taken at varying times of the day and stored 
frozen for future measurements (15). Follow-up data on mortality and disease status 
was ascertained via registries, clinical records and other sources of clinical 
information (15).  
 
Type 2 diabetes case ascertainment and verification 
Incident type 2 diabetes cases were identified using multiple sources of evidence 
including self-report, linkage to primary-care registers, secondary-care registers, 
medication use, hospital admissions and mortality data. Cases were considered 
verified if confirmed by at least two independent sources. Cases in Denmark and 
Sweden were identified via local and national diabetes and pharmaceutical registers 
and hence all ascertained cases were considered to be verified (15). Follow-up was 
censored at date of diagnosis, 31st December 2007 or date of death, whichever 
occurred first.  
 
 
Laboratory measurements 
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Serum samples were used to measure the biomarkers in all centers, except Umea 
(n=1,845) where only plasma samples were available and only ferritin could be 
measured. All measurements were done at the Stichting Huisartsen Laboratorium, 
Etten-Leur, the Netherlands. Cobas® assays were used to measure ferritin 
(electrochemiluminescence immunoassay sandwich principle), iron (colorimetric 
assay) and transferrin (immunoturbidimetric assay) on a Roche Hitachi Modular P 
analyzer. The assay range for serum iron was 0.9-179 μmol/l, that for transferrin was 
1.26-63 μmol/l and that for ferritin was 0.5-2000 μg/l. Results below the lower 
detection limit for each assay were considered missing (2 results for serum iron 
only). TSAT was calculated as [iron (μmol/L) x 100)] / [transferrin (g/L) x 22.75]. 
Cobas® assays on the same analyzer were also used to measure hsCRP (particle-
enhanced immunoturbidimetric assay), ALT and AST (UV test) and GGT (enzymatic 
calorimetric assay). Quality control was based on the Westgard rules (17). 
 
Statistical analysis 
Baseline characteristics of individuals were compared across sex-specific quartiles 
of the ferritin distribution in the subcohort. Distributions of ferritin levels were 
compared by sex, as well as BMI and waist circumference categories in the 
subcohort. After log-transformation of variables with skewed distributions (ferritin, 
hsCRP, GGT and alcohol consumption), a multivariable regression model adjusted 
for age, center and sex and unadjusted Pearson correlation coefficients were used to 
describe the relationships between each biomarker of iron metabolism and each 
other and with possible confounders.  
 
10 
 
We estimated associations of differences (defined in Table 3) in ferritin, iron and 
transferrin in natural units with the risk of type 2 diabetes using Prentice weighted 
Cox regression models with age as the underlying timescale, fitted separately within 
each country, with estimates combined across countries using random effects meta-
analysis. Prentice weighted Cox regression is used to analyze a case-cohort study to 
take account of the enrichment of incident cases occurring outside of the random 
subcohort. We used hazard ratios as estimates of risk. We used a cut-off of 
TSAT≥45% as this is the threshold recommended by clinical guidelines to rule out 
genetic causes of hyperferritinemia (18) and also the threshold at which substantial 
levels of non-transferrin bound iron appear (14). We fitted three different models with 
increasing levels of adjustment for key potential confounders, namely, age, study 
center, BMI, physical activity, smoking status, level of education, hsCRP, ALT and 
GGT. AST and ALT were highly correlated (r=0.75) and as AST is less specific for 
liver disease than ALT, so we only included ALT in the model. We included 
participants who had data available for the relevant biomarker and all these potential 
confounders, unless stated otherwise. In order to compare results with pooled 
estimates from a recent meta-analysis (3), results were also reported for the top 
quintile compared to the lowest quintile of ferritin (sex-specific quintiles defined in the 
subcohort). Because the distribution of ferritin is substantially different in men and 
women in the general population, we also reported results for one sex-specific 
standard deviation of ferritin. We also presented hazard ratios for various cut-offs of 
TSAT and for a 5% higher level of TSAT. Adjusted and unadjusted cubic splines 
were generated for the association of each biomarker with type 2 diabetes in men 
and women. The splines were calculated between the 1st and 99th percentile of the 
11 
 
relevant biomarker with knots at the 5th, 25th, 75th and 95th percentiles and the 
median as the reference.  
 
The association of ferritin with type 2 diabetes was also estimated in a restricted 
sample of individuals who did not present signs of common correlates of 
hyperferritinemia, namely inflammation, liver disease, high alcohol consumption and 
obesity (n=10,958). These were defined as individuals with hsCRP <10 mg/L, ALT 
and AST ≤40 U/L, GGT ≤60 U/L (men), ≤40 U/L (women) and a low to moderate self-
reported alcohol consumption (<30 g/day in men and <20 g/day in women, as 
suggested by the European Association for the Study of Liver) (19). The same 
association was also estimated after excluding individuals with ferritin levels higher 
than 1000 μg/L (n=125), in an attempt to exclude individuals with conditions of 
extreme iron overload, such as HHC.  
 
For biomarkers which showed a significant association with type 2 diabetes in men 
and women, p-values for interaction between the biomarker and variables related to 
iron metabolism were estimated by including a parameter representing the 
interaction between the biomarker (continuous) and the variable of interest 
(categorical) in Prentice-weighted Cox regression models adjusted for age, sex and 
center fitted within each country, with estimates combined using random effects 
meta-analysis. Hazard ratios of type 2 diabetes for each biomarker were then 
estimated within strata for each variable of interest. Waist circumference was 
categorized according to sex-specific cut-offs (20) and BMI according to the World 
Health Organization classification (defined in Figure 2). 
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Sensitivity analyses were carried out for the association of ferritin and type 2 
diabetes, as it is the one where confounding is most likely, adjusting additionally for 
menopausal status, alcohol consumption and red meat consumption. Information on 
waist circumference and family history of type 2 diabetes were missing in 
respectively 7.3% and 50.4% of the study population, mainly because it had not 
been assessed in certain centers. Therefore, these variables were not included as 
covariates in the main models, but sensitivity analyses were carried out among 
individuals with information on waist circumference (n=23,122) and family history 
(n=11,565). All analyses were performed using Stata 13. 
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RESULTS 
 
Of all 27,779 InterAct participants (12,403 incident type 2 diabetes cases), between 
23,554 (10,371 cases) and 25,113 individuals (11,052 cases) had data available for 
the relevant biomarkers and all the covariates for the main models and were 
included in this analysis. The median (interquartile range) of ferritin in the subcohort 
was 144 (80-241) μg/l in men and 58 (29-107) μg/l in women. 8.31% of men and 
4.78% of women in the subcohort had a TSAT level ≥45%. Summary statistics of 
biomarkers and baseline characteristics of participants by quartiles of ferritin in the 
subcohort are detailed in Tables 1 and 2. Individuals in the highest quartile of ferritin 
were older, consumed more alcohol, had lower levels of transferrin and higher levels 
of TSAT and liver enzymes compared to individuals in the rest of the subcohort. 
Leaner individuals had smaller SDs of ferritin (Supplementary Table 1). In linear 
regression analyses adjusting for age, sex and center (Supplementary Table S2), 
ferritin was associated with each of the other iron markers and with all of the possible 
confounding factors with the exception of estimated dietary iron intake for which the 
relationship was weak. TSAT was strongly correlated with serum iron (r=0.91) and 
inversely correlated with hsCRP (r=-0.15). Estimated dietary iron intake was only 
weakly associated with ferritin and not with the other iron biomarkers.  
 
Hazard ratios (HR) of type 2 diabetes for each biomarker are summarized in Table 3 
and Supplementary Figure S1 and the adjusted and unadjusted associations 
estimated from spline regression are displayed in Figure 1 and Supplementary 
Figure S2, respectively. A 100 μg/L higher ferritin level was associated with a 
higher risk (95% CI) of type 2 diabetes in men, 1.07 (1.01; 1.12) and women, 1.12 
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(1.05; 1.19), after adjusting for age, center, BMI, physical activity, smoking status, 
level of education, hsCRP, ALT and GGT. Hazard ratios per sex-specific standard 
deviation of ferritin were similar in men and women (Supplementary Table S3). The 
spline analyses showed that the strengths of the associations were weakened by the 
adjustment (particularly for ferritin), while the shapes of the associations remained 
generally similar. A TSAT≥45% versus <45% was associated with a significantly 
lower risk of type 2 diabetes in women only. Using cut offs of 50% and 55% for TSAT 
or estimating hazard ratios per 5% higher level of TSAT did not substantially affect 
the results, but the association was no longer statistically significant in women using 
cut-offs of 50% or 55% (Supplementary Table S4). A higher serum iron level was 
not associated with type 2 diabetes. A higher transferrin level was associated with a 
higher risk of type 2 diabetes in men, 1.11 (1.00; 1.24), and women, 1.22 (1.12; 
1.33). The associations of ferritin and transferrin with type 2 diabetes were most 
attenuated after adjusting for BMI and ALT (data not shown). Sensitivity analyses 
excluding individuals who developed diabetes within the first two years of follow-up 
did not change the results (data not shown). 
 
Restricting the analyses to individuals not presenting any sign of overt inflammation, 
liver disease, high alcohol consumption or obesity, moderately weakened the 
association of ferritin with type 2 diabetes in men to a HR (95% CI) of 1.04 (0.96; 
1.12), while the association remained similar in women with a HR of 1.12 (1.02; 1.24) 
per 100 μg/L higher level of ferritin, adjusted for age, center, type 2 diabetes risk 
factors, hsCRP and liver enzymes. Among individuals with ferritin levels lower than 
1000 μg/L, the association of ferritin with type 2 diabetes was similar in men with a 
HR of 1.09 (1.02; 1.15), but a higher HR in women of 1.26 (1.15; 1.38).  
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In age and center adjusted analyses, associations for ferritin, TSAT, serum iron and 
transferrin were stronger in women, compared to men, although differences did not 
reach conventional levels of statistical significance for transferrin (pinteraction=0.004, 
<0.001, 0.01, and 0.47 respectively). There was a stronger association of ferritin with 
type 2 diabetes among leaner individuals (Figure 2), with a significant interaction 
with waist circumference (pinteraction=0.004) and BMI (pinteraction<0.001).  Transferrin 
showed a stronger association with type 2 diabetes among individuals at extremes of 
waist circumference (pinteraction=0.034). There was no interaction of either ferritin or 
transferrin with menopausal status, estimated dietary iron or alcohol consumption 
and no interaction of transferrin with BMI.  
 
Adjusting for menopausal status, alcohol consumption, red meat intake, family 
history of type 2 diabetes or waist circumference did not substantially modify the 
association of ferritin in men or women (Supplementary Table S5).  
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CONCLUSIONS 
 
This study, which was conducted in a large European population, showed that higher 
ferritin and transferrin levels were associated with an increased risk of type 2 
diabetes in men and women. Even among individuals showing no signs of overt 
inflammation, liver disease, high alcohol consumption or obesity, ferritin was 
associated with type 2 diabetes in women, but to a lesser extent in men. An elevated 
TSAT was associated with a lower risk of type 2 diabetes in women when a cut-off of 
45% was used and serum iron was not associated with type 2 diabetes. The 
associations of all four iron biomarkers with type 2 diabetes were stronger in women 
than in men. This likely reflects physiological differences in iron metabolism and 
biomarker distributions between men and women, causing the relative risk of 
absolute biomarker differences to be greater in women. 
 
The association of ferritin with type 2 diabetes has previously been reported, but the 
association from the latest meta-analysis of prospective studies was stronger and 
less precise than that found in this present study, with HR (95% CI) of 1.73 (1.35; 
2.22) for the top quintile compared to the lower quintile in the meta-analysis (3). This 
difference may be explained by the much larger number of cases in the present 
study (11,052 versus 3,391), and the lack of adjustment for liver enzymes in many of 
the studies included in the meta-analysis. The stronger association in women than in 
men using natural units was no longer apparent when using standardized units, 
suggesting that the stronger association is a reflection of the different distributions of 
ferritin in men and women in the population. Contrary to suggestions from previous 
studies (21,22) we did not observe a threshold effect of ferritin with incident type 2 
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diabetes in the InterAct study, but rather a linear association, with an increased risk 
even at levels of ferritin considered within the reference range. For the first time, we 
demonstrated that ferritin showed a relatively stronger association among leaner 
individuals. This may be due to the fact that leaner individuals have a lower absolute 
risk of type 2 diabetes and that the standard deviation of ferritin is smaller among 
leaner individuals, hence the relative risk of ferritin is larger in leaner than in 
overweight or obese individuals. The association of higher transferrin with type 2 
diabetes has previously been reported in a small prospective study, which also 
showed the absence of association of serum iron with type 2 diabetes (23).  
 
Nevertheless, our study found a more complex relationship between TSAT and 
diabetes. Results from existing prospective studies of TSAT with type 2 diabetes are 
conflicting. A study from NHANES did not find any association between TSAT and 
type 2 diabetes using different cut-offs for TSAT (24). In contrast, a meta-analysis of 
three Danish studies found that TSAT≥50% was associated with a higher risk of type 
2 diabetes (25). However, these were relatively small studies with fewer than 1,500 
cases in each study. This is the first prospective study to show that an elevated 
TSAT is associated with a lower risk of type 2 diabetes, which was statistically 
significant in women only. Recent cross-sectional studies have shown a similar 
association of high ferritin and low TSAT among individuals with ‘pre-diabetes’ (26–
28).  TSAT is a useful biomarker of iron metabolism in addition to ferritin (26), as 
TSAT levels are less affected by inflammation than ferritin (29) and are thought to 
reflect levels of non-transferrin bound iron (13,14). In patients with HHC, which is 
characterized by high iron absorption, TSAT is elevated first, followed by ferritin once 
tissue iron accumulation has occurred (1). Non-transferrin bound iron is thought to 
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be an important source of organ iron deposition and toxicity as it is avidly taken up 
by tissues, independently of the transferrin receptor (14) and levels have been 
shown to be higher in patients with type 2 diabetes compared to controls (30). 
However, the direction of association between TSAT and type 2 diabetes observed 
in this study does not support a simple association between increased iron 
absorption or higher non-transferrin bound iron and type 2 diabetes. This may be 
because not all cases of iron overload are characterized by an elevated TSAT. For 
example, the insulin resistance-associated hepatic iron overload syndrome is 
characterized by mild to moderate hepatic iron overload on liver biopsy, generally 
with an elevated ferritin but a normal TSAT (31–33). Alternatively, a higher TSAT 
could reflect more successful scavenging of non-transferrin bound iron and therefore 
be protective for type 2 diabetes.  Finally, as TSAT is inversely associated with 
inflammation, negative confounding by inflammation may mask an association of 
TSAT with type 2 diabetes.  
 
High levels of ferritin and transferrin are markers of high and low iron stores, 
respectively and were strongly inversely correlated. However, they were both 
positively associated with type 2 diabetes in this study. Participants with low ferritin 
levels had a lower risk of developing type 2 diabetes compared to the median, 
suggesting that low iron stores per se are not associated with a higher risk of type 2 
diabetes. While a cross-talk between iron and insulin resistance is likely, the initiating 
factor of the vicious circle remains unclear (34). Cross-sectional studies showed that 
ferritin was correlated with 2-hour glucose concentration and inversely with insulin 
sensitivity in individuals without type 2 diabetes (8), as well as inversely with 
adiponectin (35,36). A recent study showed that ferritin and transferrin were 
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prospectively associated with indices of hepatic, muscular and adipocyte insulin 
resistance (37). Some experimental studies report an upregulation of transferrin 
expression by insulin in human hepatocytes (38,39), while other studies suggest an 
antagonist effect of transferrin on insulin action, leading to insulin resistance (40). 
We suggest that the association of both ferritin and transferrin with incident type 2 
diabetes could be explained, at least in part, by insulin resistance. This is supported 
by the fact that in the present study, the strength of the associations of ferritin and 
transferrin with type 2 diabetes was most strongly attenuated after adjustment for 
BMI and ALT, which are both associated with insulin resistance (41,42).  
 
Taken together, these observed associations of TSAT and transferrin with type 2 
diabetes do not support the clear role of iron in the pathogenesis of type 2 diabetes 
that might have been suggested by the association of ferritin. Case series in the 20th 
century reported a relatively high prevalence of diabetes among patients with HHC, 
which formed an important basis for the hypothesized role of iron in the 
pathogenesis of type 2 diabetes. However, the Hemochromatosis and Iron Overload 
Screening Study found the sex- and age-adjusted prevalence of self-reported 
diabetes similar in C282Y homozygotes and in participants without HFE C282Y and 
H63D mutations (43–46). Also, genetic studies to date show that C282Y is not 
associated with type 2 diabetes, while H63D is modestly associated (47,48). HHC 
was historically defined in the 19th century as the co-occurrence of cirrhosis, diabetes 
and skin pigmentation and this triad became the sine qua non of HHC until the end 
of the 20th century. Because diabetes was part of the triad used to define HHC, 
clinicians would look for type 2 diabetes in people they suspect of having HHC. This 
creates an ascertainment bias, which is less likely to occur now that genetic testing 
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is the gold standard for the diagnosis of HHC. An alternative explanation to the 
associations observed in this study is that disorders of iron overload caused by 
different mechanisms show different associations with type 2 diabetes, but that these 
differences may not be captured by the use of biomarkers. However, the use of more 
invasive measures of iron stores necessary to distinguish these disorders is unlikely 
to be feasible on a large scale.  
 
This is the first prospective study to comprehensively report the association of four 
commonly used clinical measures of iron stores and type 2 diabetes. It is limited by 
the fact that we had a single measure of TSAT for each individual and that most 
samples were non-fasting, which may have affected the dichotomous categorization 
of TSAT. However, this applied to all participants irrespective of their diabetes status, 
and the consequence would be non-differential error which would under-estimate the 
strength of the association between TSAT and type 2 diabetes. This could contribute 
to the lack of observed association in men, but does not explain the association in 
women. Also, we were unable to exclude participants with clinically diagnosed HHC. 
However, although HFE mutations are common, the clinical penetrance of the 
disease is extremely low (49), therefore this is unlikely to have substantially affected 
our results. As for all observational studies, we cannot exclude reverse causality or 
residual confounding as potential explanations for our findings. However, there was 
no relationship between the iron biomarkers and HbA1c at baseline in the subcohort 
and sensitivity analyses excluding individuals who developed diabetes within the first 
two years of follow-up did not change the results. These observations lessen the 
likelihood of reverse causality. 
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In conclusion, the observed pattern of association of these biomarkers of iron 
metabolism and type 2 diabetes suggests a more complex relationship than simply 
high iron stores being a risk factor for type 2 diabetes. It remains to be clarified 
whether the associations of higher ferritin and transferrin with type 2 diabetes aredue 
to a causal role of iron in the pathogenesis of type 2 diabetes, or whether it simply 
reflects the underlying progression of insulin resistance. The genetics of iron 
metabolism in general and specifically of different disorders of iron metabolism 
based on their mechanisms may be useful in addressing these questions which are 
difficult to answer using traditional observational designs. 
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Table 1. Baseline characteristics by quartiles of ferritin in men in the subcohort 
(n=5,697) 
 
  
 
Ferritin quartiles (Range of ferritin, μg/L) 
 
p for 
difference 
across 
quartiles* 
 
Overall 
subcohort 
    Q1 (4-80) Q2 (81-144) Q3 (145-241) Q4 (242-2283) 
  
Age (years) 52.2 (8.9) 52.1 (9.1) 52.8 (9.1) 53.5 (8.3) <0.001 52.9 (8.9) 
BMI (kg/m2) 26.2 (3.5) 26.4 (3.5) 26.6 (3.5) 27.4 (3.6) <0.001 26.6 (3.6) 
Education (%) 
    
0.0001  
 Low 7.9 6.1 4.9 4.4 
 
5.6 
 Primary 37.0 35.0 31.5 32.0 
 
34.1 
 Vocational 21.4 21.4 22.7 25.3 
 
22.8 
 Secondary 13.2 13.3 13.7 12.3 
 
13.3 
 Higher 20.5 24.1 27.2 26.1 
 
24.2 
Physical Activity 
(%)     
0.006  
 Inactive 17.5 17.8 19.7 18.9 
 
18.7 
 Moderately 
inactive 
28.6 29.9 30.7 34.0 
 
30.9 
 Moderately 
active 
25.9 27.1 24.2 24.8 
 
25.5 
 Active 28.0 25.1 25.2 22.3 
 
24.9 
Smoking (%) 
    
0.7  
 Never 34.5 32.8 30.6 29.2 
 
31.7 
 Former 32.5 32.5 37.7 42.6 
 
36.7 
 Smoker 33.0 34.7 31.6 28.2 
 
31.6 
Family history of 
T2D (%) 
12.1 16.2 12.8 19.3 <0.001 15.5 
Alcohol intake 
(g/day) † 
10.5 (2.2;24.6) 12.3 (3.4;28.3) 15.2 (5.4;36.2) 19.3 (7.1;40.2) <0.001 13.5 (4.0;32.4) 
Dietary iron intake 
(mg/day) 
15.3 (4.9) 15.4 (5.0) 15.2 (5.0) 15.3 (5.0) 0.9 15.3 (5.0) 
Biomarkers (mean, SD) 
 TSAT (%) 26.8 (9.9) 29.7 (9.8) 30.8 (9.2) 33.8 (12.5) <0.001 30.3 (10.7) 
 Iron (μmol/L) 17.3 (6.0) 17.8 (5.7) 18.2 (5.5) 19.2 (6.6) <0.001 18.1 (6.0) 
 Transferrin (g/L) 2.9 (0.4) 2.7 (0.4) 2.6 (0.3) 2.5 (0.4) <0.001 2.7 (0.4) 
 Glucose 
(mmol/L) 
5.0 (1.6) 5.1 (1.3) 5.2 (1.5) 5.6 (1.5) <0.001 5.2 (1.5) 
 HbA1c 
(mmol/mol) 
36.4 (4.8) 36.3 (4.5) 36.4 (5.4) 36.3 (6.4) 0.97 36.4 (5.3) 
 hsCRP (mg/L) † 0.9 (0.5;1.9) 1.0(0.5;2.1) 1.1 (0.6;2.5) 1.4 (0.7;2.9) <0.001 1.1 (0.5;2.3) 
 ALT (U/L) 22.6 (10.4) 24.4 (11.8) 26.6 (13.6) 32.9 (20.0) <0.001 26.6 (14.9) 
 AST (U/L) 29.3 (7.6) 30.0 (8.4) 30.9 (9.5) 35.0 (15.3) <0.001 31.3 (10.9) 
  GGT (U/L) † 24.0 
(18.0;34.0) 
26.0 
(19.0;40.0) 
29.5 
(21.0;46.0) 
36.0 
(25.0;60.0) 
<0.001 
28.0 
(20.0;44.0) 
 
Data shown are mean (standard deviation) or median (interquartile range) for skewed variables 
marked † 
* ANOVA for normally distributed continuous variables, Kruskal-Wallis test for continuous variables 
with skewed distribution (†) and Chi
2
 for categorical variables 
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Table 2. Baseline characteristics by quartiles of ferritin in women in the subcohort 
(n=9,485) 
  
 
Ferritin quartiles (Range of ferritin, μg/L) 
 
p for 
difference 
across 
quartiles* 
Overall 
subcohort 
   Q1 (1-29) Q2 (30-58) Q3 (59-107) Q4 (108-3017) 
  
Age (years) 47.2 (8.0) 50.0 (9.4) 54.1 (8.7) 57.0 (7.8) <0.001 52.1 (9.3) 
BMI (kg/m2) 25.5 (4.4) 25.4 (4.6) 25.4 (4.4) 26.4 (4.6) <0.001 25.7 (4.5) 
Education (%) 
    
0.002  
 Low 12.4 10.2 7.3 6.3 
 
8.9 
 Primary 33.1 30.5 32.6 34.2 
 
32.8 
 Vocational 20.3 22.0 24.4 26.6 
 
23.4 
 Secondary 15.6 16.6 18.0 17.0 
 
16.6 
 Higher 18.6 20.7 17.8 15.9 
 
18.3 
Physical Activity (%) 
    
0.0008  
 Inactive 30.1 26.4 26.8 24.5 
 
27.0 
 Moderately inactive 34.2 35.4 34.8 36.2 
 
35.1 
 Moderately active 20.3 20.9 20.4 21.1 
 
20.9 
 Active 15.4 17.3 18.0 18.2 
 
17.1 
Smoking (%) 
    
0.0006  
 Never 59.7 54.6 54.1 56.2 
 
56.0 
 Former 20.2 21.3 21.7 22.4 
 
21.4 
 Smoker 20.1 24.1 24.3 21.4 
 
22.6 
Family history of T2D 
(%) 
19.7 18.7 19.5 23.5 0.1 20.5 
Alcohol intake (g/day) † 
1.7 (0;7.2) 2.7 (0.2;10.6) 3.6 (0.4;12.0) 5.1 (0.6;13.5) <0.001 
3.0 
(0.2;11.1) 
Estimated dietary iron 
intake (mg/day) 
12.3 (3.6) 12.4 (3.7) 12.3 (3.6) 12.0 (3.4) 0.009 12.2 (3.6) 
Biomarkers (mean, SD) 
 TSAT (%) 20.8 (10.5) 27.2 (9.7) 28.5 (9.0) 30.5 (10.3) <0.001 26.7 (10.5) 
 Iron (μmol/L) 14.3 (6.7) 17.1 (6.0) 17.3 (5.4) 17.8 (5.8) <0.001 16.6 (6.2) 
 Transferrin (g/L) 3.1 (0.5) 2.8 (0.4) 2.7 (0.4) 2.6 (0.4) <0.001 2.8 (0.4) 
 Glucose (mmol/L) 4.7 (1.3) 4.7 (1.0) 4.8 (1.2) 5.0 (1.3) <0.001 4.8 (1.2) 
 HbA1c (mmol/mol) 35.6 (4.6) 35.5 (4.3) 36.4 (4.7) 36.9 (5.8) <0.001 36.1 (4.9) 
 hsCRP (mg/L) † 
0.9 (0.4;1.9) 1.0 (0.5;2.2) 1.1 (0.6;2.5) 1.4 (0.7;3.1) <0.001 
1.1 
(0.5;2.4) 
 ALT (U/L) 17.0 (8.7) 17.7 (9.0) 19.5 (12.4) 21.9 (15.1) <0.001 19.0 (11.7) 
 AST (U/L) 25.7 (9.9) 26.1 (10.1) 27.3 (7.9) 29.1 (13.7) <0.001 27.1 (10.7) 
  GGT (U/L) † 14.0 
(11.0;18.0) 
16.0  
(12.0; 22.0) 
18.0 
(14.0;26.0) 
20.0  
(15.0;31.0) 
<0.001 
17.0 
(13.0;24.0) 
 
Data shown are mean (standard deviation) or median (interquartile range) for skewed variables 
marked † 
* ANOVA for normally distributed continuous variables, Kruskal-Wallis test for continuous variables 
with skewed distribution (†) and Chi
2
 for categorical variables 
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Table 3. Hazard ratio (95% confidence intervals) of Type 2 Diabetes for the higher 
biomarker level as stated, by sex and meta-analyzed across countries. 
Sex Biomarker Model HR (95% CI) p value Heterogeneity I
2  
(%) 
Men      
 
Ferritin (per 100 μg/L ) 1 1.18 (1.12; 1.25) <0.001  
 
 2 1.13 (1.08; 1.19) <0.001  
 
 3 1.06 (1.01; 1.12) 0.021 72.20 
 TSAT≥45% 
 
1 0.99 (0.81; 1.20) 0.885  
 
2 1.06 (0.86; 1.32) 0.579  
 
3 0.90 (0.75; 1.08) 0.259 0.0 
 Serum Iron (per 5 
μmol/L) 
 
1 1.03 (0.98; 1.08) 0.293  
 
2 1.04 (0.98; 1.11) 0.166  
 
3 1.00 (0.94; 1.07) 0.976 49.40 
 Transferrin (per 0.5 g/L) 
 
1 1.20 (1.12; 1.30) <0.001  
 
2 1.16 (1.05; 1.29) 0.003  
 
3 1.11 (1.00; 1.23) 0.061 54.50 
Women      
 Ferritin (per 100 μg/L) 
 
1 1.31 (1.22; 1.41) <0.001  
 
2 1.22 (1.14; 1.31) <0.001  
 
3 1.12 (1.05; 1.19) 0.001 53.50 
 TSAT≥45% 
 
1 0.54 (0.44; 0.67) <0.001  
 
2 0.73 (0.59; 0.91) 0.004  
 
3 0.68 (0.54; 0.86) 0.002 0.0 
 Serum Iron (per 5 
μmol/L) 
 
1 0.92 (0.89; 0.95) <0.001  
 
2 1.02 (0.97; 1.07) 0.403  
 
3 1.00 (0.95; 1.05) 0.869 38.00 
 Transferrin (per 0.5 g/L) 
 
1 1.30 (1.21; 1.41) <0.001  
 
2 1.24 (1.15; 1.34) <0.001  
 
3 1.22 (1.12; 1.33) <0.001 55.30 
Men and Women     
 Ferritin (upper vs. lower 
quintile)† 
 
1* 2.46 (2.05; 2.96) <0.001  
 2* 1.77 (1.57; 2.00) <0.001  
 3* 1.36 (1.20; 1.54) <0.001 5.3 
Model 1: age and center adjusted 
Model 2: further adjustment for BMI, physical activity, smoking status and level of education 
Model 3: further adjustment for hsCRP, ALT and GGT 
*additional adjustment for sex 
†Ferritin quintile cut-points: 
Men (μg/L): ≤68, >68-117, >117-177, >177-270, >270 
Women (μg/L): ≤24, >24-45, >45-73, >73-121, >121 
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Legends for Figures and Supplementary Tables and Figures. 
 
Figure 1. Adjusted Hazard ratios for Type 2 Diabetes (T2D) by Ferritin, TSAT, 
Serum Iron and Transferrin levels in men and women.  
Figure 2. Hazard ratios of type 2 diabetes per 100 μg/L of ferritin and 0.5 g/L of 
transferrin in men and women by strata adjusting for age, sex and center and meta-
analyzed across countries. 
 
Supplementary Figure S1. Hazard ratios (95% confidence intervals) of Type 2 
Diabetes for the higher biomarker level as stated, by sex and meta-analyzed across 
countries. 
Supplementary Figure S2. Unadjusted Hazard ratios for Type 2 Diabetes (T2D) by 
Ferritin, TSAT, Serum Iron and Transferrin levels in men and women.  
 
Supplementary Table S1. Means (SD) and median (interquartile range) of Ferritin 
(μg/L) by BMI and waist circumference categories in men and women in the 
subcohort. 
Supplementary Table S2. Multivariable linear regressions (age, sex and center 
adjusted) and correlations (unadjusted) of each biomarker with other variables in the 
subcohort. 
Supplementary Table S3. Hazard ratios (95% confidence intervals) of Type 2 
Diabetes per sex-specific standard deviation of Ferritin in men and women. 
Supplementary Table S4. Hazard ratios (95% confidence intervals) of Type 2 
Diabetes for Transferrin Saturation using varying cut-off points and per 5% higher 
level of TSAT in men and women. 
Supplementary Table S5. Hazard ratio (95% confidence intervals) of Type 2 
Diabetes for 100 μg/L higher level of ferritin by sex in specific subgroups, adjusting 
for age, center, BMI, physical activity, smoking status, level of education, hsCRP, 
ALT and GGT and specified additional covariates. 
 
 
